Personalis Net Income Over Time
| PSNL Stock | USD 8.21 0.00 0.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Personalis Performance and Personalis Correlation. Personalis | Build AI portfolio with Personalis Stock |
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Personalis. Anticipated expansion of Personalis directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Personalis assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.83) | Revenue Per Share | Quarterly Revenue Growth (0.44) | Return On Assets | Return On Equity |
Understanding Personalis requires distinguishing between market price and book value, where the latter reflects Personalis's accounting equity. The concept of intrinsic value - what Personalis' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Personalis' price substantially above or below its fundamental value.
It's important to distinguish between Personalis' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Personalis should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Personalis' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Personalis and related stocks such as Myriad Genetics, CareDx Inc, and Fulgent Genetics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MYGN | (5.9 M) | 100.7 M | 112.2 M | 147.1 M | 176.2 M | 80.2 M | 125.3 M | 21.8 M | 131 M | 4.6 M | (223.7 M) | (27.2 M) | (112 M) | (263.3 M) | (127.3 M) | (114.6 M) | (108.8 M) |
| CDNA | (5.1 M) | (5.1 M) | (5.1 M) | (3.5 M) | 781 K | (13.7 M) | (39.5 M) | (55.5 M) | (46.8 M) | (22 M) | (18.7 M) | (30.7 M) | (76.6 M) | (190.3 M) | 52.5 M | 47.3 M | 49.7 M |
| FLGT | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (8.3 M) | (5.4 M) | (2.7 M) | (4.5 M) | 366 K | 214.3 M | 104.3 M | 143.4 M | (167.8 M) | (42.7 M) | (49.1 M) | (46.7 M) |
| CSTL | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (6.4 M) | 5.3 M | (10.3 M) | (31.3 M) | (67.1 M) | (57.5 M) | 18.2 M | 16.4 M | 17.2 M |
| TYRA | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (9.3 M) | (26.1 M) | (51.7 M) | (69.1 M) | (86.5 M) | (77.8 M) | (73.9 M) |
| RZLT | (49.3 K) | (49.3 K) | (6.7 M) | (9.7 M) | (11.4 M) | (14.9 M) | (20.3 M) | (29.9 M) | (30.4 M) | (20.3 M) | (20.9 M) | (41.1 M) | (51.8 M) | (68.5 M) | (74.4 M) | (67 M) | (63.6 M) |
| EVH | (19.3 M) | (19.3 M) | (19.3 M) | 20 M | (25.2 M) | 332.5 M | (159.7 M) | (60.7 M) | (52.7 M) | (302 M) | (334.2 M) | (37.6 M) | (19.2 M) | (113 M) | (61.6 M) | (55.5 M) | (58.2 M) |
| GERN | (10.7 M) | (96.9 M) | (68.9 M) | (38.4 M) | (35.7 M) | 46 K | (29.5 M) | (27.9 M) | (27 M) | (63.6 M) | (75.6 M) | (116.1 M) | (141.9 M) | (184.1 M) | (174.6 M) | (157.1 M) | (149.3 M) |
| MRVI | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (8.5 M) | 76.9 M | 182 M | 220.2 M | (119 M) | (144.8 M) | (130.4 M) | (123.8 M) |
| BFLY | (50.8 M) | (50.8 M) | (50.8 M) | (50.8 M) | (50.8 M) | (50.8 M) | (50.8 M) | (50.8 M) | (50.8 M) | (99.6 M) | (162.7 M) | (32.4 M) | (168.7 M) | (133.7 M) | (72.5 M) | (65.2 M) | (68.5 M) |
Personalis and related stocks such as Myriad Genetics, CareDx Inc, and Fulgent Genetics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Personalis financial statement analysis. It represents the amount of money remaining after all of Personalis operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Personalis | PSNL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 6600 Dumbarton Circle, |
| Exchange | NASDAQ Exchange |
USD 8.21
Check out Personalis Performance and Personalis Correlation. For more information on how to buy Personalis Stock please use our How to buy in Personalis Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Personalis technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.